GlaxoSmithKline teamed up with venture capital firm Avalon Ventures to provide funding to up to 10 drug-discovery startup firms that will be established by Avalon within three years. GSK will contribute up to $465 million while Avalon will provide as much as $30 million. GSK will have an option to purchase each startup.

Full Story:

Related Summaries